menu
    • menu
    [{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"DNTH103","moa":"C1","graph1":"Immunology","graph2":"Phase I","graph3":"Dianthus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dianthus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Dianthus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Hesperos","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"DNTH103","moa":"C1","graph1":"Immunology","graph2":"Phase II","graph3":"Dianthus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dianthus Therapeutics \/ Hesperos","highestDevelopmentStatusID":"8","companyTruncated":"Dianthus Therapeutics \/ Hesperos"},{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"DNTH103","moa":"C1","graph1":"Neurology","graph2":"Phase I","graph3":"Dianthus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dianthus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Dianthus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Private Placement","leadProduct":"DNTH103","moa":"C1","graph1":"Immunology","graph2":"Phase II","graph3":"Dianthus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dianthus Therapeutics \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"8","companyTruncated":"Dianthus Therapeutics \/ Fidelity Management & Research Company"},{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Private Placement","leadProduct":"DNTH103","moa":"C1","graph1":"Immunology","graph2":"Phase II","graph3":"Dianthus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dianthus Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Dianthus Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"DNTH103","moa":"C1","graph1":"Immunology","graph2":"Phase II","graph3":"Dianthus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dianthus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dianthus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"DNTH103","moa":"C1s","graph1":"Immunology","graph2":"Phase II","graph3":"Dianthus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dianthus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dianthus Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Dianthus Therapeutics

    cayman pipeline prospector

    Virtual Booth

    Contact Supplier

    Check all FDF Dossiers for
    this supplier

    Contact Us
    PharmaScopic.com

    Click to view the API/FDF
    Pricing Demo Dashboard
    Menu

    Dianthus Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Dianthus Therapeutics

                            U.S.A arrow
                            PEGS Boston Summit
                            Not Confirmed

                            Dianthus Therapeutics

                            U.S.A arrow
                            PEGS Boston Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DNTH103

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dianthus Completes Enrollment in DNTH103 Phase 2 MaGic Trial for MG

                            Details : DNTH103 is an investigational, potent mAb selectively target the classical pathway by inhibiting only the active form of the C1s protein, for treating myasthenia gravis.

                            Product Name : DNTH103

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            May 05, 2025

                            Lead Product(s) : DNTH103

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Dianthus Therapeutics

                            U.S.A arrow
                            PEGS Boston Summit
                            Not Confirmed

                            Dianthus Therapeutics

                            U.S.A arrow
                            PEGS Boston Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DNTH103

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dianthus Therapeutics Gets FDA Clearance for Phase 2 Trial of DNTH103 in MMN

                            Details : DNTH103 is a potent monoclonal antibody engineered to selectively inhibitis only the active form of the C1s protein. It is being evaluated for the treatment of Multifocal Motor Neuropathy.

                            Product Name : DNTH103

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            December 06, 2024

                            Lead Product(s) : DNTH103

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Dianthus Therapeutics

                            U.S.A arrow
                            PEGS Boston Summit
                            Not Confirmed

                            Dianthus Therapeutics

                            U.S.A arrow
                            PEGS Boston Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DNTH103

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Hesperos

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hesperos Supports Investigational Product for Phase II Trial with Human-on-a-Chip®

                            Details : DNTH103 is an investigational, potent mAb engineered to selectively targets by inhibiting only the active form of the C1s protein. It is being evaluated for generalized myasthenia gravis.

                            Product Name : DNTH103

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            September 24, 2024

                            Lead Product(s) : DNTH103

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Hesperos

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Dianthus Therapeutics

                            U.S.A arrow
                            PEGS Boston Summit
                            Not Confirmed

                            Dianthus Therapeutics

                            U.S.A arrow
                            PEGS Boston Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DNTH103

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dianthus Initiates Phase 2 MaGic Trial Of DNTH103 in Myasthenia Gravis

                            Details : DNTH103 is an investigational, clinical-stage monoclonal antibody targeting the classical pathway by inhibiting the active form of C1s protein, evaluated for generalized myasthenia gravis.

                            Product Name : DNTH103

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            February 26, 2024

                            Lead Product(s) : DNTH103

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Dianthus Therapeutics

                            U.S.A arrow
                            PEGS Boston Summit
                            Not Confirmed

                            Dianthus Therapeutics

                            U.S.A arrow
                            PEGS Boston Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DNTH103

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Jefferies

                            Deal Size : $230.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Dianthus Therapeutics Announces $230 Million Private Placement

                            Details : The net proceeds will be used for the clinical development of DNTH103. It is a selective inhibitor of the active C1s protein for the treatment of neuromuscular & autoimmune disorders.

                            Product Name : DNTH103

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            January 22, 2024

                            Lead Product(s) : DNTH103

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Jefferies

                            Deal Size : $230.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Dianthus Therapeutics

                            U.S.A arrow
                            PEGS Boston Summit
                            Not Confirmed

                            Dianthus Therapeutics

                            U.S.A arrow
                            PEGS Boston Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DNTH103

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Fidelity Management & Research Company

                            Deal Size : $70.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement

                            Details : The net financing will be used to fund DNTH103 through multiple clinical data catalysts including Phase 1 in healthy volunteers, and Phase 2 trials in generalized Myasthenia Gravis and other indications.

                            Product Name : DNTH103

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            March 05, 2023

                            Lead Product(s) : DNTH103

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Fidelity Management & Research Company

                            Deal Size : $70.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Dianthus Therapeutics

                            U.S.A arrow
                            PEGS Boston Summit
                            Not Confirmed

                            Dianthus Therapeutics

                            U.S.A arrow
                            PEGS Boston Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DNTH103

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dianthus Therapeutics Announces First Participant Dosed in Phase 1 Trial of DNTH103, a Selective Inhibitor of ...

                            Details : DNTH103 is a next-generation monoclonal antibody that selectively targets only the active form of the C1s protein in the classical complement pathway. DNTH103 is designed as an infrequent and convenient subcutaneous injection.

                            Product Name : DNTH103

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            November 30, 2022

                            Lead Product(s) : DNTH103

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth